Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.

Ryota ShibakiYuichi OzawaSusumu NoguchiYusuke MurakamiEri TakaseYuichiro AzumaMasaru MaebeyaTakeya SugimotoAtsushi HayataTakahiro HayakawaShinya TamakiMasanori NakanishiShunsuke TeraokaHiroaki Akamatsu

Published in: Cancer medicine (2022)

Pre-ILS increased the risk of lung injury in patients of non-small cell lung cancer treated with osimertinib, while the severity of lung injury was not clearly affected by the presence of pre-ILS.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
advanced non small cell lung cancer
epidermal growth factor receptor
tyrosine kinase